Keywords
How to Cite
Abstract
Coronary heart disease (CHD) and concomitant arterial hypertension (AH) are key problems of modern cardiology. At the heart of atherogenesis, which plays a decisive role in the progression of both pathologies, is oxidative stress and endothelial dysfunction. Folic acid and meldonium are drugs that can minimize the activity of these processes when they are added together to standard treatment. CHD significantly reduces the quality of life of patients. Assessment of quality of life with the help of specialized questionnaires makes it possible to comprehensively assess the effectiveness of treatment of patients. The aim of the study. To evaluate the quality of life in patients with stable coronary heart disease with and without concomitant arterial hypertension against the background of additional combined use of folic acid and meldonium. Materials and methods. The study included 66 patients with stable CAD and hypertension. The patients were divided into 2 groups: 1) 40 patients with stable CAD and concomitant hypertension; 2) 26 patients with stable CAD without concomitant hypertension. The quality of life of patients was evaluated using the Seattle Angina Questionnaire (SAQ) against the background of standard treatment and with the addition of folic acid and meldonium. Results and discussion. The baseline level of quality of life of patients with coronary artery disease and concomitant hypertension was lower than that of patients with coronary artery disease without hypertension. Improvement in the quality of life was noted in all groups of patients, however, when meldonium and folic acid were added to standard therapy, this increase was significantly higher, especially among patients without concomitant hypertension. Conclusions. The use of a combination of folic acid with meldonium as part of standard therapy for 6 months reliably improves the quality of life of patients with coronary artery disease regardless of the presence of concomitant hypertension. The SAQ questionnaire has demonstrated its effectiveness in the comprehensive examination of patients with CAD and can be applied for use in the daily practice of a physician
References
NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.
Іпатов АВ, Коробкін ЮІ, Дроздова ІВ, Ханюкова Я, Сидорова МГ. Хвороби системи кровообігу: провідні тенденції динаміки інвалідності. Український кардіологічний журнал. 2012;1:36-41.
Гандзюк В. Динаміка захворюваності та поширеності серцево-судинних хвороб серед населення України на сучасному етапі: національний та регіональний аспекти. ВСГООЗ [інтернет]. 08, Грудень 2014 [cited 26, Жовтень 2022];(2). Available at: https://ojs.tdmu.edu.ua/index.php/visnyk-gigieny/article/view/3376
Ivanyuk АV, Orlova NM. Хвороби системи кровообігу як причина втрати трудового потенціалу Київської області. ВСГООЗ [інтернет]. 19, Березень 2021 [cited 26, Жовтень 2022];(4):26-33. Available at: https://ojs.tdmu.edu.ua/index.php/visnyk-gigieny/article/view/11906
Reeh J, Therming CB, Heitmann M, Hojberg S, Sorum C, Bech J, et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. Eur Heart J 2018;40:1426-1435.
Rosendorff C, Black HR, Cannon CP, et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
Le J, Dorstyn DS, Mpofu E, Prior E, Tully PJ. Health-related quality of life in coronary heart disease: a systematic review and meta-analysis mapped against the International Classification of Functioning, Disability and Health. Qual Life Res. 2018 Oct;27(10):2491-2503. doi: 10.1007/s11136-018-1885-5. Epub 2018 May 19. Erratum in: Qual Life Res. 2018 Jun 6;: PMID: 29779143.
Wardoku R, Blair C, Demmer R, Prizment A. Association between physical inactivity and health-related quality of life in adults with coronary heart disease. Maturitas. 2019 Oct;128:36-42. doi: 10.1016/j.maturitas.2019.07.005. Epub 2019 Jul 11. PMID: 31561820; PMCID: PMC7261413.
Zhang H, Wang Y, Cai X, Tang N, Wei S, Yang Y. Family functioning and health-related quality of life of inpatients with coronary heart disease: a cross-sectional study in Lanzhou city, China. BMC Cardiovasc Disord. 2022 Sep 6;22(1):397. doi: 10.1186/s12872-022-02844-x. PMID: 36068504; PMCID: PMC9446873.
Barham A, Ibraheem R, Zyoud SH. Cardiac self-efficacy and quality of life in patients with coronary heart disease: a cross-sectional study from Palestine. BMC Cardiovasc Disord. 2019 Dec 13;19(1):290. doi: 10.1186/s12872-019-01281-7. PMID: 31835995; PMCID: PMC6909462.
Wang L, Wu YQ, Tang X, Li N, He L, Cao Y, Chen DF, Hu YH. Profile and Correlates of Health-related Quality of Life in Chinese Patients with Coronary Heart Disease. Chin Med J (Engl). 2015 Jul 20;128(14):1853-61. doi: 10.4103/0366-6999.160486. PMID: 26168822; PMCID: PMC4717935.
Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell Longev. 2014, article ID 360438.
Dzerve V; MILSS I Study Group. A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial «MILSS I». Medicina (Kaunas). 2011;47(10):544-51. PMID: 22186118.
Bastani A, Rajabi S, Daliran A, Saadat H, Karimi-Busheri F. Oxidant and antioxidant status in coronary artery disease. Biomed. Rep., 2018;9(4):327-332.
Béchir M, Enseleit F, Chenevard R, Muntwyler J, Lüscher TF, Noll G. Folic Acid improves baroreceptor sensitivity in hypertension. J Cardiovasc Pharmacol. 2005 Jan;45(1):44-8.